Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Jalish M. Riyad, Thomas Weber

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


In the last two decades, recombinant adeno-associated virus has emerged as the most popular gene therapy vector. Recently AAV gene therapy has been approved by the FDA for the treatment of two rare genetic disorders, namely the early childhood blindness disease Leber congenital amaurosis and spinal muscular atrophy (SMA). As is the case for the treatment of SMA, if the AAV vector must be administered systemically, very high vector doses are often required for therapeutic efficacy. But higher vector doses inevitably increase the risk of adverse events. The tragic death of three children in a clinical trial to treat X-linked myotubular myopathy with an AAV vector has thrown this limitation into sharp relief. Regardless of the precise cause(s) that led to the death of the two children, it is critical that we develop better AAV vectors to achieve therapeutic levels of expression with lower vector doses. To transduce successfully a target cell, AAV has to overcome both systemic as well as cellular roadblocks. In this review, we discuss some of the most prominent cellular roadblocks that AAV must get past to deliver successfully its therapeutic payload. We also highlight recent advancements in our knowledge of AAV biology that can potentially be harnessed to improve AAV vector performance and thereby make AAV gene therapy safer.

Original languageEnglish
Pages (from-to)683-696
Number of pages14
JournalGene Therapy
Issue number12
StatePublished - Dec 2021


Dive into the research topics of 'Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions'. Together they form a unique fingerprint.

Cite this